Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Mar 30;6(9):6977-88.
doi: 10.18632/oncotarget.3166.

Distinct anti-oncogenic effect of various microRNAs in different mouse models of liver cancer

Affiliations

Distinct anti-oncogenic effect of various microRNAs in different mouse models of liver cancer

Junyan Tao et al. Oncotarget. .

Abstract

Deregulation of microRNAs (miRNAs) is a typical feature of human hepatocellular carcinoma (HCC). However, the in vivo relevance of miRNAs along hepatocarcinogenesis remains largely unknown. Here, we show that liver tumors induced in mice by c-Myc overexpression or AKT/Ras co-expression exhibit distinct miRNA expression profiles. Among the downregulated miRNAs, eight (miR-101, miR-107, miR-122, miR-29, miR-365, miR-375, miR-378, and miR-802) were selected and their tumor suppressor activity was determined by overexpressing each of them together with c-Myc or AKT/Ras oncogenes in mouse livers via hydrodynamic transfection. The tumor suppressor activity of these microRNAs was extremely heterogeneous in c-Myc and AKT/Ras mice: while miR-378 had no tumor suppressor activity, miR-107, mir-122, miR-29, miR-365 and miR-802 exhibited weak to moderate tumor suppressor potential. Noticeably, miR-375 showed limited antineoplastic activity against c-Myc driven tumorigenesis, whereas it strongly inhibited AKT/Ras induced hepatocarcinogenesis. Furthermore, miR-101 significantly suppressed both c-Myc and AKT/Ras liver tumor development. Altogether, the present data demonstrate that different oncogenes induce distinct miRNA patterns, whose modulation differently affects hepatocarcinogenesis depending on the driving oncogenes. Finally, our findings support a strong tumor suppressor activity of miR-101 in liver cancer models regardless of the driver oncogenes involved, thus representing a promising therapeutic target in human HCC.

Keywords: AKT; HCC; Ras; c-Myc; mouse liver cancer.

PubMed Disclaimer

Conflict of interest statement

CONFLICT OF INTEREST

The authors have declared that no competing interests exist.

Figures

Figure 1
Figure 1. c-Myc and AKT/Ras induced liver tumors exhibit distinct miRNA profiles
(A) Unsupervised hierarchical clustering analysis using 599 mouse miRNAs in normal livers from wild-type (WT) mice and liver tumors from c-Myc and AKT/Ras injected mice. (B) Scattering Plot of miRNAs in liver tumors from c-Myc and AKT/Ras injected mice. Red spots refer to miRNAs with significant difference (unpaired t-test, p < 0.05) between c-Myc and AKT/Ras injected mice. (C) Venn Diagram analysis of c-Myc signature and AKT/Ras signature. The signature was obtained from the miRNA profiling comparison of c-Myc-tumor (or AKT/Ras tumor) and non-tumor liver from wild-type mice. Unpaired t-test was used and miRNAs with p-value < 0.001 and fold change ≥ 2 or ≤ 0.5 were included in the signature.
Figure 2
Figure 2. AKT/Ras and c-Myc mouse liver tumor signatures are related to patients’ HCC prognosis
(A) Kaplan-Meier analysis of overall survival and disease-free survival in HCC cases (n = 227) based on the classification of group 1 and group 2 by the AKT/Ras signature. (B) Kaplan-Meier analysis of overall survival and disease-free survival in HCC cases (n = 227) based on the classification of group 1 and group 2 by the c-Myc signature. Cox-Mantel log-rank test was performed.
Figure 3
Figure 3. Overall diagram of study design to investigate tumor suppressor activity of miRNA in mice
Each of the eight miRNAs was co-expressed with c-Myc (A) or AKT/Ras (B) oncogenes in the mouse liver via hydrodynamic transfection. pT3-EF1α empty vector was also co-injected with c-Myc (c-Myc/pT3) or AKT/Ras (AKT/Ras/pT3) as a control. w.p.i: weeks post injection.
Figure 4
Figure 4. Overexpression of miR-375 strongly inhibits AKT/Ras but not c-Myc induced liver tumor formation in mice
(A) Macroscopic (upper panel) and microscopic (lower panel) appearance of livers from c-Myc/pT3 mice and c-Myc/miR-375 mice stained with H&E (100X), insets (400X). (B) Kaplan Meier survival curve of c-Myc/pT3 and c-Myc/miR-375 mouse cohort. (C) Macroscopic (upper panel) and microscopic (lower panel) appearance of livers from AKT/Ras/PT3 mice and AKT/Ras/miR-375 mice stained with H&E (100X). (D) Kaplan Meier survival curve of AKT/Ras/pT3 and AKT/Ras/miR-375 mouse cohort.
Figure 5
Figure 5. Overexpression of miR-101 efficiently inhibits c-Myc and AKT/Ras induced liver tumor development
(A) Macroscopic (upper panel) and microscopic (lower panel) appearance of livers from c-Myc/pT3 mice and c-Myc/miR-101 mice stained with H&E (100X), insets (400 X). (B) Kaplan Meier survival curve of c-Myc/pT3 and c-Myc/miR-101 mouse cohort. (C) Macroscopic (upper panel) and microscopic (lower panel) appearance of livers from AKT/Ras/PT3 mice and AKT/Ras/miR-101 mice stained with H&E (100X). (D) Kaplan Meier survival curve of AKT/Ras/pT3 and AKT/Ras/miR-101 mouse cohort.

References

    1. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264–1273. e1261. - PMC - PubMed
    1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. New Engl J Med. 1999;340:745–750. - PubMed
    1. Llovet JM, Bruix J. Novel advancements in the management of hepatocellular carcinoma in. J Hepatol. 2008;48:S20–S37. - PubMed
    1. Rampone B, Schiavone B, Martino A, Viviano C, Confuorto G. Current management strategy of hepatocellular carcinoma. World J Gastroenterol. 2009;15:3210–3216. - PMC - PubMed
    1. Llovet JM, Schwartz M, Mazzaferro V. Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis. 2005;25:181–200. - PubMed

Publication types

MeSH terms